Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…


Novartis takes license on Celyad's allogeneic CAR T cells

Celyad, a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s …


Bone Therapeutics Granted EUR 2.3 Million by the Walloon Region

Bone cell therapy company Bone Therapeutics receives 2.3 million in funding from the Wallonian Government.

POPULAR TAGS

Bone Therapeutics grows both locally and internationally to become a champion of bone regenerative medicine

Written by GK on in the category news with the tags , .


Walloon bone cell therapy company, Bone Therapeutics (BOTHE), is moving into their new headquarters in Gosselies. The new 3000m² facility is part of a larger project, the Walloon Cell Therapy Platform. “Our objective is to become a champion of bone regenerative medicine with international aspirations.” said Enrico Bastianelli, CEO of Bone Therapeutics. After the successful initial public offering on Euronext Brussels and Paris, the company has established its US based subsidiary, Bone Therapeutics USA Inc. in Boston, Massachusetts. This is the first milestone in the initiation of Bone Therapeutics’ clinical trials in the US. “This further strengthens the international reach of our innovative pipeline of bone cell therapy products" further explains Bastianelli.

Bone Therapeutics is a bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention and is investigating therapeutic approaches to address conditions as spinal fusion, osteonecrosis and osteoporosis. The current standard-of-care in this field often involves major surgeries with long recovery times. To overcome this, Bone Therapeutics develops innovative regenerative products containing bone-forming cells (osteoblasts), administrable via a minimally invasive procedure. Bone Therapeutics’ autologous product PREOB® is currently in two Phase III studies for the treatment of osteonecrosis and non-union fractures and in Phase II development for the treatment of severe osteoporosis. Its allogeneic cell therapy product ALLOB® is being tested in Phase II for delayed-union fractures and for use in spine fusion surgery.

Read more about: , .

RELATED ARTICLES
IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…


Novartis takes license on Celyad's allogeneic CAR T cells

Celyad, a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s …


Bone Therapeutics Granted EUR 2.3 Million by the Walloon Region

Bone cell therapy company Bone Therapeutics receives 2.3 million in funding from the Wallonian Government.

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

UGent Turnstone V-Bio Ventures Biowin Janssen XpandInnovation Flanders.bio GSK Itera Life Science KU Leuven

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.